Skip to main content

OCGN

Stock
Health Care
Biotechnology

Performance overview

OCGN Price
Price Chart

Forward-looking statistics

Beta
1.25
Risk
78.86%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Company info

SectorHealth Care
IndustryBiotechnology
Employees90
Market cap$411.8M

Fundamentals

Enterprise value$277.4M
Revenue$4.5M
Revenue per employee
Profit margin0.00%
Debt to equity199.97

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.20
Dividend per share
Revenue per share$0.02
Avg trading volume (30 day)$9M
Avg trading volume (10 day)$12M
Put-call ratio

Macro factor sensitivity

Growth+11.8
Credit-1.4
Liquidity-7.0
Inflation+12.7
Commodities+6.7
Interest Rates-0.8

Valuation

Dividend yield0.00%
PEG Ratio-3.68
Price to sales61.80
P/E Ratio-3.68
Enterprise Value to Revenue61.35
Price to book17.72

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day
Ex. dividend daySeptember 30, 2019

News

5 Biotech Breakthrough Stocks to Watch in 2025

After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.

Zacks Investment Research (December 23, 2024)
Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years

Ocugen Inc (NASDAQ: OCGN) announced the publication of positive pediatric Phase 2/3 study results in children aged 2–18 years for COVID-19 vaccine, Covaxin (BBV152), in The Lancet Infectious Diseases. Covaxin is developed and manufactured by Ocugen's India-based partner.

Benzinga (June 21, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free